Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 21, 2025—Tribun Health announced that its flagship web-based image management system, CaloPix, has received FDA 510(k) clearance for use with the Hamamatsu NanoZoomer S360MD and Leica Aperio GT 450 DX scanners.
May 19, 2025—Fujirebio announced that the FDA has granted 510(k) clearance for its Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test.
May 16, 2025—Roche announced FDA approval for the Ventana MET (SP44) RxDx assay, the first companion diagnostic approved to aid in determining MET protein expression in patients with non-small cell lung cancer. These patients may now be eligible for treatment with AbbVie’s c-Met targeted therapy Emrelis (telisotuzumab vedotin-tllv).
May 14, 2025—AbbVie announced that Emrelis (telisotuzumab vedotin-tllv) has been granted accelerated approval by the FDA for the treatment of adult patients with locally advanced or metastatic, nonsquamous non-small cell lung cancer with high c-Met protein overexpression who have received a prior systemic therapy.
May 8, 2025—Ibex Medical Analytics reports that a study conducted at Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution, significantly improves accuracy and efficiency in evaluating breast pathology cases (Tahir M, et al. Clin Breast Cancer. Published online March 26, 2025).
April 29, 2025—Roche announced that the FDA granted breakthrough device designation for the Ventana TROP2 (EPR20043) RxDx device, a computational pathology device.
April 24, 2025—Techcyte announced the launch of its wet mount iodine solution for research use only in the United States.
April 23, 2025—ARUP Laboratories now provides a blood test for phosphorylated tau 217 to assist in identifying whether symptoms of cognitive decline in patients ages 60 years and older are related to Alzheimer’s disease pathology.
April 23, 2025—ARUP Laboratories now provides a blood test for phosphorylated tau 217 to assist in identifying whether symptoms of cognitive decline in patients ages 60 years and older are related to Alzheimer’s disease pathology.
April 21, 2025—Diasorin announced it has received FDA 510(k) clearance for the Liaison Plex Gram-Negative Blood Culture assay, the second of the company’s three multiplex molecular panels for blood culture pathogen identification on the Liaison Plex.
